Prime Therapeutics Integrated Specialty Pharmacy Benefits
Managers should evaluate how merging medical and pharmacy data sets can curb high-cost drug spending.
Updated on Oct. 1, 2026 in Healthcare
Live Poll
Do you believe combining medical and pharmacy benefits helps reduce your personal healthcare costs?
At its September 2026 Specialty Summit, Prime Therapeutics detailed its efforts to reduce costs by integrating medical and pharmacy benefit management. The program, IntegratedRx, aims to address the rising influx of specialty drugs, which accounted for 76% of all novel FDA-approved medications in 2025.
Why it matters
Half of all specialty pharmacy spending occurs within the medical benefit, leading to siloes that complicate care management. By bridging these data gaps, companies aim to better control costs for the 10% to 13% of patients who drive over 90% of total drug expenses.
Prime Therapeutics reported a 9% reduction in total care costs through its IntegratedRx program, which services patients driving 60% of pharmacy spend. Currently, 43% of employers prioritize specialty pharmacy management as they face a surge in novel drug approvals.
The players
Prime Therapeutics
A pharmacy benefit manager owned by 19 Blue Cross Blue Shield plans that coordinates medical and pharmacy data.
Food and Drug Administration
The federal agency responsible for approving novel drug products that increasingly fall into the specialty category.
Pharmaceutical Strategies Group
An industry firm that tracks employer objectives regarding specialty pharmacy spending.
The details
The IntegratedRx program utilizes medical benefits data from Blue Cross Blue Shield plans to manage patient care paths for specific conditions like oncology and cystic fibrosis. By allowing patients to fill prescriptions through in-house pharmacies or directly at their doctor's office, the firm removes traditional administrative friction. This unified approach targets the 3% of patients responsible for 60% of pharmacy benefit spending.
Timeline
2022 marked the close of Prime Therapeutics' acquisition of Magellan Rx.
76% of novel drugs approved by the FDA were specialty products in 2025.
Prime Therapeutics held its annual Specialty Summit in September 2026.
Market Landscape
This integration strategy follows the infrastructure shift established by the 2022 acquisition of Magellan Rx by Prime Therapeutics. It aligns with broader industry efforts to manage costs by consolidating previously siloed pharmacy and medical benefit management.
Employers should review their current benefit plan structure to identify whether medical and pharmacy data are integrated. Failure to bridge these silos may prevent firms from effectively managing the high-cost patients who drive the vast majority of total drug spend.
The takeaway
Management of high-cost specialty pharmacy spend is increasingly reliant on unified medical and pharmacy data access. Operators should monitor the specific performance metrics of their benefit providers to ensure they are targeting the high-utilization patients driving most plan costs.
Further reading
For more on industry shifts in benefits management, see Healthcare.
Source note: This article includes information reported by FierceHealth.
Live Poll
Do you believe combining medical and pharmacy benefits helps reduce your personal healthcare costs?
